Fen-Phen suits grow; panel mulls MDL forum for diet-drug litigation as feds urge heart exams

Article Abstract:

Manufacturers of the diet drug popularly known as Fen-phen face a potentially huge liability in the multidistrict litigation being considered for suits. American Home Products makes and sells fenfluramine and sells dexfenfluramine under the trade names Redux and Pondimin. American estimates 4 mil people to have used Pondimin and another 2 mil people Redux. Significant cardiac effects may appear in a third of these people, according to a preliminary medical study. Interneuron Pharmaceuticals is an even more significant defendant.

Drugs and Druggists' Sundries Wholesalers, Drugs, proprietaries, and sundries, Drugs Wholesale, Health aspects, Mass tort suits, Drug wholesalers, Redux (Medication)

---

Bickering in fen-phen litigation; some plaintiffs lawyers say settlement is insufficient

Article Abstract:

Attorneys handling the multidistrict litigation of the drugs Redux and fen-phen confront a problem common to this type of litigation, that there is no formal way to coordinate state court cases with federal ones. Some of the lawyers for plaintiffs in the state court cases complain that those representing the plaintiffs in federal court, as well as the judge overseeing the cases, are mishandling matters. Control over the 1500 lawsuits nationwide, some class actions, is at issue.

Product liability, Drug therapy, Products liability

---

Will liability cloud use of thalidomide? Renewed interest for a spate of diseases, but risks remain

Article Abstract:

Celgene Corporation is leading the way in efforts by the various members of the pharmaceutical industry to approve the use of thalidomide. Thalidomide was banned in the early sixties after pregnant women given the drug gave birth to severely deformed infants. Experimental use of the drug to treat persons suffering from AID's and leprosy has lead to renewed interest in limited use of the drug.

Analysis, Laws, regulations and rules, Pharmaceutical industry, Causes of, Brazil, Birth defects, United States. Food and Drug Administration, Pharmaceutical policy, Thalidomide, Celgene Corp., CELG

Similar abstracts:

• Abstracts: Stogies no longer just for old fogies; though it's hardly PC, cigar smoking has become popular among younger lawyers
• Abstracts: Securities regulatory reform legislation. Securities Litigation Uniform Standards Act of 1998. The Private Securities Litigation Reform Act - overview, summary and new developments
• Abstracts: Sixth Circuit fashions two-part test for deductibility of administration expenses
• Abstracts: Duel of the document managers. Voice dictation software: the next generation. Case management in the spotlight
• Abstracts: Judicial review in the time of cholera. Substantive reform, judicial review, and agency resources: OSHA as a case study

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.